vs

Side-by-side financial comparison of MIND TECHNOLOGY, INC (MIND) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $9.7M, roughly 1.3× MIND TECHNOLOGY, INC). MIND TECHNOLOGY, INC runs the higher net margin — 0.6% vs -1398.3%, a 1399.0% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs -20.0%). MIND TECHNOLOGY, INC produced more free cash flow last quarter ($801.0K vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs -14.9%).

Mitcham Industries, Inc. is a company founded in 1987, and is based in Huntsville, Texas. The company markets geophysical and other equipment to seismic data acquisition contractors conducting surveys on land, marsh, and marine areas, both shallow and deep water. There are mainly two segments operating in the company, namely an Equipment Leasing segment and an Equipment Manufacturing segment. In October 2011, the Company opened a new logistics and repair facility in Budapest, Hungary, and thr...

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

MIND vs RNA — Head-to-Head

Bigger by revenue
RNA
RNA
1.3× larger
RNA
$12.5M
$9.7M
MIND
Growing faster (revenue YoY)
RNA
RNA
+454.0% gap
RNA
434.0%
-20.0%
MIND
Higher net margin
MIND
MIND
1399.0% more per $
MIND
0.6%
-1398.3%
RNA
More free cash flow
MIND
MIND
$157.7M more FCF
MIND
$801.0K
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
-14.9%
MIND

Income Statement — Q3 FY2026 vs Q3 FY2025

Metric
MIND
MIND
RNA
RNA
Revenue
$9.7M
$12.5M
Net Profit
$62.0K
$-174.4M
Gross Margin
46.6%
Operating Margin
8.0%
-1513.5%
Net Margin
0.6%
-1398.3%
Revenue YoY
-20.0%
434.0%
Net Profit YoY
-95.2%
-117.0%
EPS (diluted)
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MIND
MIND
RNA
RNA
Q4 25
$9.7M
Q3 25
$13.6M
$12.5M
Q2 25
$7.9M
$3.8M
Q1 25
$15.0M
$1.6M
Q4 24
$12.1M
$3.0M
Q3 24
$10.0M
$2.3M
Q2 24
$9.7M
$2.0M
Q1 24
$13.4M
$3.5M
Net Profit
MIND
MIND
RNA
RNA
Q4 25
$62.0K
Q3 25
$1.9M
$-174.4M
Q2 25
$-970.0K
$-157.3M
Q1 25
$2.0M
$-115.8M
Q4 24
$1.3M
$-102.3M
Q3 24
$798.0K
$-80.4M
Q2 24
$954.0K
$-70.8M
Q1 24
$1.4M
$-68.9M
Gross Margin
MIND
MIND
RNA
RNA
Q4 25
46.6%
Q3 25
50.4%
Q2 25
42.2%
Q1 25
43.5%
Q4 24
44.8%
Q3 24
47.6%
Q2 24
43.6%
Q1 24
46.7%
Operating Margin
MIND
MIND
RNA
RNA
Q4 25
8.0%
Q3 25
19.6%
-1513.5%
Q2 25
-8.3%
-4448.7%
Q1 25
18.5%
-8360.9%
Q4 24
15.5%
-4069.6%
Q3 24
14.2%
-4200.9%
Q2 24
7.5%
-4040.4%
Q1 24
17.3%
-2178.6%
Net Margin
MIND
MIND
RNA
RNA
Q4 25
0.6%
Q3 25
14.2%
-1398.3%
Q2 25
-12.3%
-4089.3%
Q1 25
13.5%
-7360.0%
Q4 24
10.7%
-3439.5%
Q3 24
8.0%
-3441.7%
Q2 24
9.9%
-3461.8%
Q1 24
10.8%
-1943.4%
EPS (diluted)
MIND
MIND
RNA
RNA
Q4 25
Q3 25
$-1.27
Q2 25
$-1.21
Q1 25
$-0.90
Q4 24
$-0.80
Q3 24
$-0.65
Q2 24
$-0.65
Q1 24
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MIND
MIND
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$19.4M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$39.9M
$1.9B
Total Assets
$47.3M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MIND
MIND
RNA
RNA
Q4 25
$19.4M
Q3 25
$7.8M
$350.2M
Q2 25
$9.2M
$243.9M
Q1 25
$5.3M
$254.2M
Q4 24
$3.5M
$219.9M
Q3 24
$1.9M
$370.2M
Q2 24
$924.0K
$575.8M
Q1 24
$5.3M
$471.4M
Stockholders' Equity
MIND
MIND
RNA
RNA
Q4 25
$39.9M
Q3 25
$28.8M
$1.9B
Q2 25
$26.6M
$1.2B
Q1 25
$27.3M
$1.3B
Q4 24
$25.2M
$1.4B
Q3 24
$24.5M
$1.5B
Q2 24
$23.6M
$1.2B
Q1 24
$22.6M
$830.9M
Total Assets
MIND
MIND
RNA
RNA
Q4 25
$47.3M
Q3 25
$35.8M
$2.1B
Q2 25
$36.2M
$1.4B
Q1 25
$36.7M
$1.5B
Q4 24
$36.1M
$1.6B
Q3 24
$37.8M
$1.6B
Q2 24
$34.9M
$1.3B
Q1 24
$33.5M
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MIND
MIND
RNA
RNA
Operating Cash FlowLast quarter
$894.0K
$-156.2M
Free Cash FlowOCF − Capex
$801.0K
$-156.9M
FCF MarginFCF / Revenue
8.3%
-1257.6%
Capex IntensityCapex / Revenue
1.0%
5.7%
Cash ConversionOCF / Net Profit
14.42×
TTM Free Cash FlowTrailing 4 quarters
$5.1M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MIND
MIND
RNA
RNA
Q4 25
$894.0K
Q3 25
$-1.2M
$-156.2M
Q2 25
$4.1M
$-199.7M
Q1 25
$2.1M
$-124.8M
Q4 24
$2.3M
$-99.9M
Q3 24
$1.1M
$-65.6M
Q2 24
$-4.8M
$-65.0M
Q1 24
$657.0K
$-70.4M
Free Cash Flow
MIND
MIND
RNA
RNA
Q4 25
$801.0K
Q3 25
$-1.3M
$-156.9M
Q2 25
$3.8M
$-203.0M
Q1 25
$1.8M
$-128.6M
Q4 24
$2.2M
$-103.8M
Q3 24
$978.0K
$-67.3M
Q2 24
$-4.8M
$-65.5M
Q1 24
$566.0K
$-71.3M
FCF Margin
MIND
MIND
RNA
RNA
Q4 25
8.3%
Q3 25
-9.9%
-1257.6%
Q2 25
48.5%
-5277.1%
Q1 25
12.2%
-8174.3%
Q4 24
18.3%
-3491.0%
Q3 24
9.7%
-2881.8%
Q2 24
-49.8%
-3204.6%
Q1 24
4.2%
-2012.3%
Capex Intensity
MIND
MIND
RNA
RNA
Q4 25
1.0%
Q3 25
1.3%
5.7%
Q2 25
3.0%
86.9%
Q1 25
1.5%
238.6%
Q4 24
0.6%
131.7%
Q3 24
0.8%
72.9%
Q2 24
0.7%
26.0%
Q1 24
0.7%
25.8%
Cash Conversion
MIND
MIND
RNA
RNA
Q4 25
14.42×
Q3 25
-0.60×
Q2 25
Q1 25
1.01×
Q4 24
1.77×
Q3 24
1.33×
Q2 24
-4.98×
Q1 24
0.46×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons